Pharmaceutical formulations of HDAC inhibitors
US9957227B2 · kind B2 · utility
0Cited by
16References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 15, 2017 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Nov 15, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.